103 related articles for article (PubMed ID: 10519248)
1. Characterization of new monoclonal antibodies against Cryptosporidium parvum sporozoites.
Camero L; Arrowood M; Shulaw W; Lal AA; Xiao L
J Eukaryot Microbiol; 1999; 46(5):58S-59S. PubMed ID: 10519248
[No Abstract] [Full Text] [Related]
2. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites.
Riggs MW; Stone AL; Yount PA; Langer RC; Arrowood MJ; Bentley DL
J Immunol; 1997 Feb; 158(4):1787-95. PubMed ID: 9029117
[TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibodies against Cryptosporidium parvum generated by hypo-osmolar electrofusion.
Flanigan TP; Wisnewski A; Wiest PM; Johnson J; Tzipori S; Hamer D; Lam N; Kresina TF
Trans Assoc Am Physicians; 1993; 106():86-90. PubMed ID: 8036749
[No Abstract] [Full Text] [Related]
4. [Studies on immunoprotection of monoclonal antibodies against Cryptosporidium parvum].
Zong H; Li W; Zhang X; Yu S; Bai B
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1999; 17(2):101-5. PubMed ID: 12563792
[TBL] [Abstract][Full Text] [Related]
5. Protective monoclonal antibodies define a distinct, conserved epitope on an apical complex exoantigen of Cryptosporidium parvum sporozoites.
Riggs MW; Yount PA; Stone AL; Langer RC
J Eukaryot Microbiol; 1996; 43(5):74S-75S. PubMed ID: 8822870
[No Abstract] [Full Text] [Related]
6. Effect of egg yolk antibody on experimental Cryptosporidium parvum infection in scid mice.
Kobayashi C; Yokoyama H; Nguyen SV; Kodama Y; Kimata T; Izeki M
Vaccine; 2004 Nov; 23(2):232-5. PubMed ID: 15531042
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition of Cryptosporidium parvum infection by human monoclonal antibodies.
Elliot BC; Wisnewski AV; Johnson J; Fenwick-Smith D; Wiest P; Hamer D; Kresina T; Flanigan TP
Infect Immun; 1997 Sep; 65(9):3933-5. PubMed ID: 9284173
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactivities with Cryptosporidium spp. by chicken monoclonal antibodies that recognize avian Eimeria spp.
Matsubayashi M; Kimata I; Iseki M; Lillehoj HS; Matsuda H; Nakanishi T; Tani H; Sasai K; Baba E
Vet Parasitol; 2005 Mar; 128(1-2):47-57. PubMed ID: 15725532
[TBL] [Abstract][Full Text] [Related]
9. Sporozoites and merozoites of Cryptosporidium parvum share a common epitope recognized by a monoclonal antibody and two-dimensional electrophoresis.
Tilley M; Upton SJ
J Protozool; 1991; 38(6):48S-49S. PubMed ID: 1726328
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibodies to Intracellular Stages of Cryptosporidium parvum Define Life Cycle Progression
Wilke G; Ravindran S; Funkhouser-Jones L; Barks J; Wang Q; VanDussen KL; Stappenbeck TS; Kuhlenschmidt TB; Kuhlenschmidt MS; Sibley LD
mSphere; 2018 Jun; 3(3):. PubMed ID: 29848759
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Cryptosporidium parvum and Cryptosporidium wrairi by reactivity with monoclonal antibodies and ability to infect severe combined immunodeficient mice.
Chrisp CE; Mason P; Perryman LE
Infect Immun; 1995 Jan; 63(1):360-2. PubMed ID: 7806379
[TBL] [Abstract][Full Text] [Related]
12. [Preparation and characterization of monoclonal antibodies against Cryptosporidium parvum].
Zong H; Li W; Zhang X; Yu S
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1998; 16(4):279-82. PubMed ID: 12078258
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing monoclonal antibody protects against Cryptosporidium parvum infection by inhibiting sporozoite attachment and invasion.
Langer RC; Riggs MW
J Eukaryot Microbiol; 1996; 43(5):76S-77S. PubMed ID: 8822871
[No Abstract] [Full Text] [Related]
14. Comparison of the host ranges and antigenicity of Cryptosporidium parvum and Cryptosporidium wrairi from guinea pigs.
Chrisp CE; Suckow MA; Fayer R; Arrowood MJ; Healey MC; Sterling CR
J Protozool; 1992; 39(3):406-9. PubMed ID: 1386385
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a high molecular weight antigen of Cryptosporidium parvum micronemes possessing epitopes that are cross-reactive with all parasitic life cycle stages.
Robert B; Antoine H; Dreze F; Coppe P; Collard A
Vet Res; 1994; 25(4):384-98. PubMed ID: 7522083
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets for detection and immunotherapy in Cryptosporidium parvum.
Boulter-Bitzer JI; Lee H; Trevors JT
Biotechnol Adv; 2007; 25(1):13-44. PubMed ID: 17055210
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a Cryptosporidium parvum sporozoite glycoprotein.
Petersen C; Gut J; Nelson RG; Leech JH
J Protozool; 1991; 38(6):20S-21S. PubMed ID: 1818168
[TBL] [Abstract][Full Text] [Related]
18. Identification and initial characterization of five Cryptosporidium parvum sporozoite antigen genes.
Petersen C; Gut J; Leech JH; Nelson RG
Infect Immun; 1992 Jun; 60(6):2343-8. PubMed ID: 1587601
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a monoclonal antibody reacting with antigen-4 domain of gp900 in Cryptosporidium parvum invasive stages.
Bonnin A; Ojcius DM; Souque P; Barnes DA; Doyle PS; Gut J; Nelson RG; Petersen C; Dubremetz JF
Parasitol Res; 2001 Aug; 87(8):589-92. PubMed ID: 11510991
[TBL] [Abstract][Full Text] [Related]
20. In vitro detection of anti-Cryptosporidium parvum antibody secreting cells by polyclonal activation of human tonsil mononuclear cells.
Comby E; Favennec L; Kapel N; Brasseur P; Gobert JG; Ballet JJ
J Eukaryot Microbiol; 1994; 41(5):29S-30S. PubMed ID: 7804231
[No Abstract] [Full Text] [Related]
[Next] [New Search]
